Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age. - Wikidata - awgldk - TriplyDB

Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age.

Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age.

http://www.wikidata.org/entity/Q35649092

about

Wheeze as an adverse event in pediatric vaccine and drug randomized controlled trials: A systematic review Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.Impact of pneumococcal conjugate vaccination on otitis media: a systematic review The Saudi Thoracic Society pneumococcal vaccination guidelines-2016.Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era.Expanding prevention of invasive meningococcal disease.Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia.Antibiotic treatment of acute otitis media in pediatrics.Impact of implementing French antibiotic guidelines for acute respiratory-tract infections in a paediatric emergency department, 2005-2009.Impact of pneumococcal conjugate vaccines on microbial epidemiology and clinical outcomes of acute otitis media.Prevalence of Human Bocavirus in Africa and Other Developing Countries between 2005 and 2016: A Potential Emerging Viral Pathogen for Diarrhea

P2860

Q26796334-9FC3F2C1-D554-40D4-B284-00EC1002FF51 Q33909172-8E3205C6-C185-4EA0-8DDF-B76723A11009 Q34407129-84E73DDE-9BA7-45D8-86A1-A239EB52AA3F Q35977422-150B8311-8D58-4B51-A4AA-DB99F226C7B1 Q36861485-84AF38F6-0383-4088-A643-C570B5B107D6 Q37316015-E683FB3F-AE7E-4FDD-9B68-39ACEA3E8C87 Q37503239-6C2053F2-0E2C-42B2-A5FB-76CB5D552588 Q37608307-D159CD0C-4639-432D-95C0-28EEE7D341B3 Q37613616-BD8E342E-4108-4443-9330-C37933350A2A Q37621054-AF2BB837-2760-4BD2-9E6B-3B8AEF9A6374 Q39749485-36A1F145-CE89-4016-B9DB-D80E28DCC560 Q45823762-AD6A3EE0-FAA9-4141-90A5-052FFA4CAC93 Q51168324-ACF9BB60-C2F3-4E01-880F-87CA63F6F89C Q57112691-93989BAB-AD40-4895-A871-37B9B075BC68

P2860

Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age.

http://www.wikidata.org/entity/Q35649092

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Impact on respiratory tract in ...... at 3, 5 and 11 months of age.

@ast

Impact on respiratory tract in ...... at 3, 5 and 11 months of age.

@en

type

label

Impact on respiratory tract in ...... at 3, 5 and 11 months of age.

@ast

Impact on respiratory tract in ...... at 3, 5 and 11 months of age.

@en

prefLabel

Impact on respiratory tract in ...... at 3, 5 and 11 months of age.

@ast

Impact on respiratory tract in ...... at 3, 5 and 11 months of age.

@en

P1433

Q35649092-3D43D3D9-79FD-42E8-B761-22496C9F87DA

P1476

Q35649092-0E3E6CB1-4DF8-4947-8368-F9C07B461D46

P2093

Q35649092-1062D381-C0C6-4114-90DC-7DD481AF8FF7

Q35649092-7870280A-457B-444B-A4AA-FAD9A01C9815

Q35649092-8449B448-EFBE-471B-8A92-496CBC6B5F02

Q35649092-8FD2279A-6D44-4B7B-AFC9-83DEDA6A07B8

Q35649092-99033127-75E8-45B4-8057-9ACB746F93FE

Q35649092-AD874499-59E3-4029-A6A9-4CFDB95DDCC7

Q35649092-E12AB2E8-5814-4C31-9CD4-63941A54C849

Q35649092-FEF5D20D-8EA7-43DA-B9C3-215F40C201CA

P2860

Q35649092-0FEBC9E3-9E74-4A14-9DDD-838070B3419A

Q35649092-127ACCC2-0660-4B23-BE85-0787EFF14C6D

Q35649092-19FB2A52-8D84-4015-994A-7C93E18BD64E

Q35649092-1BC7C75B-052A-44EF-8C5B-768B9F8A417E

Q35649092-2B1164CD-13B4-49F2-9F7F-C419FFF92B55

Q35649092-2BBB6218-F770-47CE-AEF1-551F39DDC476

Q35649092-2C3A4B54-4225-4BD6-A6D7-C50AAA64466F

Q35649092-30EBB080-DA6E-415F-8314-43FDB9D3FCAC

Q35649092-312C5CEA-66BE-48F5-BA5B-12D723E4F7DB

Q35649092-325F0CC1-D447-45AC-A2DA-8F70FFD9055D

P2888

Q35649092-E972EFD5-03C8-4F05-86D2-2DF8F4604372

P304

Q35649092-6A86AAF6-1ACA-47C3-A190-545EA79401E3

P31

Q35649092-6C5198FB-8C4A-4B1C-83A1-ECE770D08447

P356

Q35649092-0BC71646-8A57-4FBB-BB86-646EFB037A9D

P478

Q35649092-384F992D-962E-4508-B544-11E2E9DB3595

P50

Q35649092-97C5A56D-EE04-4783-B00D-776738831C5F

P577

Q35649092-3E002862-68B2-4C2F-BCA7-1BCA76E234AD

P5875

Q35649092-20484D57-91A0-4B69-A180-6C4199F1B2FC

P6179

Q35649092-314C7AF5-8870-42EA-AA52-B8718FCB3E76

P698

Q35649092-91EBAEF7-6829-4AC1-81FC-A3C30DB1BF5B

P932

Q35649092-0250F673-5E40-4CCA-8CA6-0BBD78574BCD

P356

P1433

Respiratory Research

P1476

Impact on respiratory tract in ...... at 3, 5 and 11 months of age.

@en

P2093

Alessandro Lizioli

http://www.w3.org/2001/XMLSchema#string

Alessandro Rognoni

http://www.w3.org/2001/XMLSchema#string

Annalisa Lastrico

http://www.w3.org/2001/XMLSchema#string

Claudia Tagliabue

http://www.w3.org/2001/XMLSchema#string

Enrica Begliatti

http://www.w3.org/2001/XMLSchema#string

Laura Cesati

http://www.w3.org/2001/XMLSchema#string

Susanna Esposito

http://www.w3.org/2001/XMLSchema#string

Vittorio Carreri

http://www.w3.org/2001/XMLSchema#string

P2860

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.

Efficacy of a pneumococcal conjugate vaccine against acute otitis media.

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.

Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus.

Community-acquired pneumonia in children.

Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance.

The potential indirect effect of conjugate pneumococcal vaccines.

Paediatric community-acquired pneumonia: current concept in pharmacological control.

P2888

P304

12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1465-9921-8-12

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Nicola Principi

P577

2007-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6491573

http://www.w3.org/2001/XMLSchema#string

P6179

1043878044

http://www.w3.org/2001/XMLSchema#string

P698

17313667

http://www.w3.org/2001/XMLSchema#string

P932

1804265

http://www.w3.org/2001/XMLSchema#string